Pharmaceuticals & Drugs · Founded 1993 · www.unickfix-a-form.com · BSE 541503 · · ISIN INE250G01010
No Notes Added Yet
Here's a structured overview of Unick Fix-A-Form And Printers Ltd. based on the provided information.
Important Note: The company name "Unick Fix-A-Form And Printers Ltd." strongly suggests a primary business in printing, particularly specialized forms. The provided sector and industry are "Pharmaceuticals & Drugs." This analysis will proceed assuming the company's core operations are in specialized printing and packaging, with a significant potential focus on serving the pharmaceutical sector given the classification. If the company were truly a drug manufacturer, its name would be highly misleading.
1. Business Overview
Unick Fix-A-Form And Printers Ltd. is primarily engaged in the printing business. Given its name, its core operations likely involve specialized printing services, possibly focusing on "Fix-A-Form" type products (which could imply innovative or multi-part business forms, integrated labels, or specialized document solutions). If classified under the "Pharmaceuticals & Drugs" sector, it's highly probable that the company specializes in providing printing and packaging solutions for the pharmaceutical industry. This could include printing of labels, cartons, patient information leaflets (PILs), security printing for anti-counterfeiting measures on drug packaging, and other specialized packaging components required by pharmaceutical manufacturers. The company makes money by selling its printed products and services to its clientele.
2. Key Segments / Revenue Mix
Specific key segments and their revenue contributions are not publicly disclosed based on the limited information. However, based on the company name and industry classification, potential segments could include:
Pharmaceutical Packaging & Leaflet Printing
Specialized Business Forms & Document Solutions
Security Printing (if applicable to prevent counterfeiting, especially relevant for pharma)
Commercial Printing (general, if diversified)
3. Industry & Positioning
If primarily a specialized printing and packaging company serving the pharmaceutical sector, Unick operates in a segment of the broader packaging industry that is characterized by stringent quality controls, regulatory compliance, and a need for precision. The pharmaceutical packaging market in India is growing, driven by the expanding healthcare sector, increased drug production, and stricter regulations around product information and anti-counterfeiting. This segment can be less fragmented than general commercial printing.
Positioning: Without specific market share data, it's difficult to ascertain its exact position. It likely competes with other specialized packaging and label printers. Success in this niche often depends on client relationships, quality assurance, regulatory adherence, and potentially proprietary printing technologies or processes (like "Fix-A-Form").
4. Competitive Advantage (Moat)
Potential competitive advantages for Unick could include:
Specialization & Expertise: Deep knowledge and established processes for printing complex pharmaceutical labels, leaflets, and cartons, adhering to regulatory standards.
Client Relationships: Long-standing relationships with pharmaceutical companies, which can have high switching costs due to strict qualification processes for suppliers.
Proprietary Products/Processes: If "Fix-A-Form" represents a unique or patented printing solution, it could offer a niche advantage.
Quality & Compliance: A proven track record of meeting stringent quality and regulatory requirements in the pharmaceutical sector.
5. Growth Drivers
Key factors that can drive Unick's growth over the next 3-5 years include:
Growth of Indian Pharmaceutical Industry: Increased drug production, R&D, and exports will directly drive demand for pharmaceutical packaging and printing services.
Regulatory Changes: Stricter regulations for drug labeling, serialization, and anti-counterfeiting measures (e.g., track and trace) will require specialized printing solutions.
Healthcare Expansion: General expansion of healthcare access and consumption in India.
Premiumization of Packaging: Demand for higher quality, more intricate, or sustainable packaging solutions.
6. Risks
Key business risks for Unick include:
Competition: Intense competition from other specialized packaging and label printers.
Raw Material Price Volatility: Fluctuations in prices of paper, ink, and other printing consumables can impact margins.
Technological Obsolescence: Rapid advancements in printing technology requiring continuous investment.
Regulatory Changes (Adverse): Changes in pharmaceutical packaging regulations could necessitate significant operational adjustments or investments.
Economic Downturn: A slowdown in the broader economy or the pharmaceutical sector could impact demand for printing services.
Dependency on Key Clients: Potential over-reliance on a few large pharmaceutical clients.
7. Management & Ownership
Specific details about the promoters and management quality are not available. In many Indian companies, promoters typically hold significant ownership stakes and often play an active role in management. Without further information, it is not possible to assess management quality or the detailed ownership structure.
8. Outlook
Unick Fix-A-Form And Printers Ltd. appears to operate in a specialized niche within the printing and packaging industry, likely catering to the growing pharmaceutical sector. The bull case rests on its ability to leverage its specialized expertise and client relationships to capitalize on the sustained growth of the Indian pharmaceutical industry and increasing demand for high-quality, compliant packaging. Its focus on specialized forms or products (implied by "Fix-A-Form") could provide a distinct market position. The bear case highlights risks such as intense competition, raw material price volatility, the need for continuous technological upgrades, and potential over-reliance on specific client segments or changing regulatory environments. Its ability to maintain competitive advantages through quality, service, and potentially proprietary solutions will be crucial for sustained performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 15 | 16 | 15 | 12 | 13 | 17 | 15 | 12 | 15 | 19 |
| Other Income | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 15 | 16 | 15 | 13 | 13 | 17 | 15 | 12 | 15 | 19 |
| Total Expenditure | 12 | 13 | 13 | 11 | 10 | 14 | 13 | 12 | 13 | 16 |
| Operating Profit | 3 | 3 | 2 | 1 | 3 | 3 | 2 | 1 | 2 | 3 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 2 | 1 | -0 | 1 | 2 | 0 | -1 | 0 | 1 |
| Provision for Tax | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 |
| Profit After Tax | 1 | 1 | 1 | -0 | 1 | 1 | 1 | -1 | -0 | 1 |
| Adjustments | 0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | 0 | -0 |
| Profit After Adjustments | 1 | 1 | 1 | -0 | 1 | 1 | 1 | -1 | -0 | 1 |
| Adjusted Earnings Per Share | 2.1 | 2.1 | 1.1 | -0.3 | 1.9 | 2 | 0.9 | -1 | -0.4 | 2 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 22 | 25 | 28 | 29 | 38 | 48 | 56 | 69 | 66 | 56 | 56 | 61 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Total Income | 22 | 26 | 28 | 29 | 38 | 49 | 57 | 70 | 67 | 56 | 56 | 61 |
| Total Expenditure | 18 | 20 | 22 | 23 | 31 | 40 | 48 | 61 | 57 | 48 | 47 | 54 |
| Operating Profit | 4 | 5 | 6 | 6 | 7 | 8 | 9 | 9 | 9 | 8 | 9 | 8 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 |
| Depreciation | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 2 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 0 |
| Provision for Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit After Tax | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 1 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | 3.9 | 5.3 | 4.2 | 4.8 | 4.1 | 3.6 | 4.8 | 1.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | -7% | 3% | 10% |
| Operating Profit CAGR | 13% | 0% | 2% | 8% |
| PAT CAGR | 50% | 0% | 0% | 12% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -40% | -8% | -2% | NA% |
| ROE Average | 8% | 7% | 9% | 11% |
| ROCE Average | 10% | 10% | 10% | 13% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 11 | 13 | 15 | 17 | 19 | 22 | 25 | 27 | 30 | 32 | 34 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 3 | 1 | 1 | 2 | 8 | 13 | 15 | 12 | 9 | 6 | 5 |
| Other Non-Current Liabilities | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 |
| Total Current Liabilities | 14 | 15 | 13 | 14 | 16 | 21 | 20 | 28 | 29 | 31 | 28 |
| Total Liabilities | 30 | 31 | 31 | 36 | 46 | 59 | 63 | 71 | 71 | 73 | 71 |
| Fixed Assets | 17 | 17 | 16 | 18 | 26 | 36 | 36 | 41 | 39 | 38 | 36 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Total Current Assets | 13 | 14 | 15 | 18 | 19 | 22 | 26 | 30 | 30 | 33 | 34 |
| Total Assets | 30 | 31 | 31 | 36 | 46 | 59 | 63 | 71 | 71 | 73 | 71 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 4 | 0 |
| Cash Flow from Operating Activities | 2 | 3 | 2 | 2 | 5 | 7 | 4 | 7 | 4 | 2 | 6 |
| Cash Flow from Investing Activities | -2 | -1 | -1 | -4 | -11 | -13 | -4 | -8 | -3 | -2 | -2 |
| Cash Flow from Financing Activities | 0 | -2 | -1 | 1 | 6 | 6 | 1 | 1 | -2 | 0 | -4 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 4 | 4 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 0 | 0 | 3.91 | 5.26 | 4.24 | 4.82 | 4.09 | 3.57 | 4.76 |
| CEPS(Rs) | 3.91 | 6.12 | 7.25 | 7.76 | 8.75 | 10.77 | 10.64 | 11.28 | 11.23 | 10.07 | 11.25 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0 | 0 | 0 | 0 | 35.28 | 40.57 | 44.85 | 49.7 | 53.44 | 56.72 | 62.28 |
| Core EBITDA Margin(%) | 16.9 | 20.06 | 21.52 | 20.16 | 18.88 | 16.71 | 14.69 | 12.12 | 13.26 | 13.9 | 16.01 |
| EBIT Margin(%) | 12.79 | 14.06 | 16.39 | 13.85 | 12.47 | 11.28 | 9.47 | 7.86 | 8.12 | 8.66 | 9.97 |
| Pre Tax Margin(%) | 6.68 | 9.3 | 12.53 | 10.56 | 8.53 | 8.15 | 5.53 | 4.89 | 4.52 | 4.67 | 6.28 |
| PAT Margin (%) | 4.3 | 6.28 | 8.04 | 7.97 | 5.6 | 5.96 | 4.15 | 3.8 | 3.39 | 3.5 | 4.66 |
| Cash Profit Margin (%) | 9.79 | 13.2 | 14.28 | 14.87 | 12.54 | 12.2 | 10.42 | 8.91 | 9.31 | 9.89 | 11.02 |
| ROA(%) | 3.15 | 5.23 | 7.26 | 6.81 | 5.24 | 5.54 | 3.82 | 3.94 | 3.17 | 2.73 | 3.64 |
| ROE(%) | 8.71 | 13.28 | 16.06 | 14.19 | 11.76 | 13.88 | 9.93 | 10.19 | 7.92 | 6.47 | 8 |
| ROCE(%) | 12.93 | 16.2 | 20.31 | 16.03 | 15.51 | 13.79 | 11.6 | 11.07 | 10.39 | 9.11 | 10.22 |
| Receivable days | 105.59 | 97.94 | 105.22 | 108.11 | 97.79 | 91.04 | 78.09 | 66.72 | 73 | 79.56 | 70.74 |
| Inventory Days | 63.03 | 53.36 | 37.85 | 31 | 27.77 | 30.39 | 35.74 | 40.88 | 53.15 | 81.55 | 104.44 |
| Payable days | 144.66 | 116.88 | 98.24 | 108.89 | 107.62 | 116.06 | 112.09 | 104.2 | 124.23 | 139.97 | 139.41 |
| PER(x) | 0 | 0 | 0 | 0 | 7.54 | 4.07 | 5.72 | 9.13 | 9.26 | 14.65 | 15.34 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0.83 | 0.53 | 0.54 | 0.88 | 0.71 | 0.92 | 1.17 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.71 | 0.53 | 0.43 | 0.48 | 0.79 | 0.66 | 0.59 | 0.64 | 0.6 | 0.86 | 1.01 |
| EV/Core EBITDA(x) | 3.86 | 2.5 | 1.92 | 2.31 | 4.09 | 3.76 | 3.75 | 4.96 | 4.29 | 5.7 | 6.21 |
| Net Sales Growth(%) | 25.77 | 16.14 | 9.48 | 2.76 | 33.67 | 26.55 | 15.71 | 23.95 | -4.69 | -15.65 | 0.29 |
| EBIT Growth(%) | 0.64 | 27.67 | 27.55 | -13.13 | 20.32 | 14.45 | -2.79 | 2.87 | -1.61 | -10.01 | 15.47 |
| PAT Growth(%) | -9.59 | 69.73 | 40.2 | 1.84 | -6.05 | 34.66 | -19.44 | 13.62 | -15.15 | -12.74 | 33.46 |
| EPS Growth(%) | 0 | 0 | 0 | 0 | -6.05 | 34.66 | -19.44 | 13.62 | -15.15 | -12.74 | 33.46 |
| Debt/Equity(x) | 0.97 | 0.72 | 0.52 | 0.55 | 0.81 | 0.99 | 0.92 | 0.89 | 0.77 | 0.74 | 0.61 |
| Current Ratio(x) | 0.9 | 0.93 | 1.16 | 1.25 | 1.2 | 1.06 | 1.3 | 1.04 | 1.05 | 1.06 | 1.22 |
| Quick Ratio(x) | 0.6 | 0.71 | 0.97 | 1.09 | 0.98 | 0.84 | 0.98 | 0.72 | 0.7 | 0.59 | 0.61 |
| Interest Cover(x) | 2.09 | 2.95 | 4.25 | 4.21 | 3.17 | 3.61 | 2.41 | 2.64 | 2.26 | 2.17 | 2.7 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.96 | 1.87 | 1.7 | 1 | 1.09 | 0.8 | 0.52 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 |
| Public | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | -7% | +3% | +10% |
| Operating Profit CAGR | +13% | 0% | +2% | +8% |
| PAT CAGR | +50% | 0% | 0% | +12% |
| Share Price CAGR | -40% | -8% | -2% | — |
| ROE Average | +8% | +7% | +9% | +11% |
| ROCE Average | +10% | +10% | +10% | +13% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 | 71.57 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 |
| Public | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 | 27.99 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.